LARIMAR THERAPEUTICS INC (LRMR)
Health Care · Rare disease / orphan drug biotechnology · NASDAQ
Larimar Therapeutics is developing a novel cell-penetrating peptide platform to treat rare, genetically driven diseases, with a lead program targeting the underlying protein deficiency in Friedreich's ataxia.
What LARIMAR THERAPEUTICS INC does
Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare diseases using its proprietary cell penetrating peptide (CPP) technology platform. The company's lead candidate, nomlabofusp, is designed to deliver frataxin protein to mitochondria in patients with Friedreich's ataxia (FA), a rare, progressive, fatal genetic disease characterized by insufficient frataxin levels. Nomlabofusp represents the first potential therapy intended to systemically increase FXN levels in FA patients, and the platform has potential applications in other rare and orphan diseases with intracellular deficiencies.
Themes: Rare disease therapeutics, Orphan drugs / Friedreich's ataxia, Mitochondrial protein delivery, Cell penetrating peptides
Fundamentals
- Price$4.18 as of 2026-08-21 close
- Market cap$434M as of 2026-08-21
- 1-year return+13.3% 2025-08-21 close $3.69 → 2026-08-21 close $4.18
- P/En/a earnings data not available
- ROE-137.4% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.69 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How LRMR compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How LARIMAR THERAPEUTICS INC looks technically
LARIMAR THERAPEUTICS INC (LRMR) is trading 7.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 42 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 8 trading days ago. It is 34.9% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 7.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +7.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.82 | $3.82 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.91 | $3.91 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 4.17. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 42 trading days ago — a "death cross", a bearish long-term signal | 42 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 7.0% above | +7.0% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 18.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 54.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($3.82 to $4.46) — its "stochastic" reading is 56 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 55.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.42 | $6.42 |
|---|---|---|
| From the 52-week high | it is 34.9% below its 52-week high (its highest price of the past year) | -34.9% |
| Above the 52-week low | it is 54.0% above its 52-week low (its lowest price of the past year) | +54.0% |
| Below the 52-week high | it is 34.9% below its highest point of the past year | 34.9% |
| Since a 20-day breakout | it made a new 20-day high about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day high about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $664.32 (set on 2015-03-20) | $664.32 |
| Given back of the 52-week move | over the past year its closes ranged ($2.81 to $5.95), and it has given back around half of its rise from last year’s low — 56% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.91 to $4.01. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. Worth noting that the whole move happened in 2 days, so it is a narrow thing to be measuring a retracement against. | 56.4% |
| From the all-time high | it is 99.4% below its all-time high | -99.4% |
| Nearest price level | it is sitting right on a resistance level at $4.20 — a price it turned at 7 times since 2025-01-31, most recently on 2026-07-22. Since 2024-08-21 it has 9 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.4% |
| All-time low | its lowest closing price on record is $1.53 (set on 2022-08-05) | $1.53 |
| Above the all-time low | it is 173.2% above its all-time low | +173.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 75% of it) | 25th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2415 between its high and its low — about 5.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2415 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.68 and $4.50 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.68 – $4.09 – $4.50 |
| Typical daily range (% of price) | its price moves about 5.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 1.1 daily ranges above its 200-day average price (7.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.51× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Gap filled | a 3.2% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 4.0 percentage points (the stock gained 6.4% while the market gained 2.3%) | +4.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 14.0 percentage points (the stock gained 17.1% while the market gained 3.1%) | +14.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 29.7 percentage points (the stock gained 40.7% while the market gained 11.1%) | +29.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 7.2 percentage points (the stock gained 13.3% while the market gained 20.5%) | -7.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.1% of the share price, which is taken to mean a barrier that gives way easily. | +13.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.36 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -4.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $4.21 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | -0.6% |
Price levels it has turned at before
LRMR last closed at $4.18 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.20 | Resistance | 0.4% above the last close | turned there 7 times · 2025-01-31 to 2026-07-22 |
| $4.29 | Resistance | 2.8% above the last close | turned there twice · 2025-01-03 to 2026-07-10 |
| $4.46 | Resistance | 6.6% above the last close | turned there three times · 2025-08-15 to 2026-08-13 |
| $3.87 | Support | 7.5% below the last close | turned there three times · 2025-10-14 to 2026-06-23 |
| $3.77 | Support | 9.7% below the last close | turned there twice · 2025-11-25 to 2026-01-28 |
| $3.67 | Support | 12.3% below the last close | turned there three times · 2024-12-26 to 2026-05-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $4.17.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $4.17 and $4.26 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $4.46.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.18 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$14.30 range $5.00 – $26.00; median $12.50
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LRMR
- Consensus EPS estimate-$0.3488 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Anaphylaxis and serious adverse events identified in ongoing clinical studies; two participants experienced serious adverse events including anaphylaxis and seizure requiring withdrawal from the study","Clinical development stage with no approved products; success depends on completing multiple ongoing clinical trials and obtaining regulatory approval, with uncertain timelines and outcomes","Limited cash runway; company anticipates current cash and recent equity financing will fund operations only into Q2 2027, requiring additional capital raises or partnership agreements"]
What changed in the latest 10-Q
AI-assisted comparison of LRMR's 10-Q filed 2026-05-14 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 2025 Annual Report filed March 19, 2026 (vs. older reference to 2024 Annual Report filed March 24, 2025)
- Newer filing mentions Pediatric Rare Disease Designation from FDA
- Newer filing states Breakthrough Therapy Designation was granted in February 2026
- Newer filing mentions FDA selected nomlabofusp for START Pilot Program participation
- Newer filing references 'skin FXN' as novel surrogate endpoint (February 2026 discussion)
- Newer filing discusses planned Type B meeting with FDA in second quarter 2026
- Newer filing discusses topline study data planned for second quarter 2026
- Newer filing discusses rolling BLA submission plan starting June 2026
- Newer filing discusses U.S. launch targeting first half of 2027
- Newer filing discusses global confirmatory Phase 3 study sites in U.S., E.U., U.K., Canada and Australia with mid-2026 dosing initiation
- Removed:
- Older filing's identifier note '(nomlabofusp is the International Nonproprietary Name and the United States Adopted Name for CTI-1601)' removed
- Older filing's reference to 'tissue frataxin' changed to just 'frataxin'
- Older filing's statement 'has the potential' changed to 'also has the potential' in newer
- Older filing's description of Phase 1 studies as 'two Phase 1 clinical studies' without 'in adults' specification
- Older filing's description of Phase 2 as 'Phase 2 dose exploration study' without 'in adults' specification
- Older filing's narrative about initiating studies in 2019 removed
- Older filing's explanation of OLE name change to OL study removed
- Older filing's December 2024 positive initial data announcement removed
- Older filing's December 2024 dose increase to 50 mg announcement removed
- Older filing's March 2025 anaphylaxis safety alert removed
- Older filing's January 2025 adolescent PK run-in study initiation details removed
- Older filing's February 2025 lyophilized drug product comparability approval removed
- Older filing's July 2025 lyophilized product introduction details removed
- Older filing's March 2025 FDA RLSE feedback details removed
- Older filing's June 2025 FDA safety database recommendation (text cut off)
- Reworded:
- Older: 'and access to the EU's Priority Medicines Program' changed to newer: 'and access to the European Medicines Agency's ("EMA's") Priority Medicines Program'
- Older: 'We have received Orphan Drug Designation and Fast Track Designation from the FDA' reordered in newer to list: 'Orphan Drug Designation, Fast Track Designation, Pediatric Rare Disease Designation and Breakthrough Therapy Designation'
- Older: 'We have been granted orphan drug designation in the European Union' changed to newer: 'been granted orphan drug designation and access to the European Medicines Agency's ("EMA's") Priority Medicines Program ("PRIME") scheme in the European Union'
- Older: 'We have also received access to the EMA's Innovative Licensing and Access Pathway ("ILAP")' changed to newer: 'We have also received access in the United Kingdom (the "UK") to the Medicines and Healthcare Regulatory Agency's ("MHRA") Innovative Licensing and Access Pathway ("ILAP")'
- Older: abbreviation 'CDER' removed and text restructured in newer version
- Older: 'U.S. Food and Drug Administration ("FDA")' changed to just 'FDA' in newer
- Notes:
- The two filings cover different fiscal periods (Q1 2026 vs. Q3 2025) and reference different annual reports (2025 vs. 2024), making direct comparison of time-sensitive developments appropriate
- The older filing text appears truncated at 'In June 2025, the FDA provided safety database recommenda' preventing full comparison of that section
- Substantial content removals in newer filing reflect focus on more recent developments rather than historical narrative from prior quarter
Risk Factors
- Added:
- Preferred stock issuance: 500,000 shares issued and outstanding as of March 31, 2026 (newer filing dated 2026-05-14)
- Preferred stock line item in balance sheet showing $1 par value and 1 share outstanding as of March 31, 2026 (newer filing dated 2026-05-14)
- Issuance of preferred stock in exchange for common stock transaction reducing common shares by 2,500,000 and increasing preferred shares by 250,000 (newer filing dated 2026-05-14)
- Preferred stock net loss per share calculation of ($3.14) in operations statement (newer filing dated 2026-05-14)
- Preferred stock weighted-average shares of 441,667 used in computing net loss per share (newer filing dated 2026-05-14)
- Line item 'Marketable securities' in balance sheet (newer filing dated 2026-05-14) replacing 'Short-term marketable securities' terminology in older filing
- Common stock issuance of 23,000,000 shares net of issuance costs for $107,616 thousand (newer filing dated 2026-05-14)
- Removed:
- Preferred stock previously showed no shares issued and outstanding as of September 30, 2025 and December 31, 2024 (older filing dated 2025-11-05)
- Multiple quarterly periods in statements of changes in stockholders' equity (June 30 2025, June 30 2024, September 30 2024 balances removed in newer filing)
- Nine-month comparative statements in operations and cash flow statements (newer filing shows only three-month period for 2026 vs 2025)
- Reworded:
- Balance sheet date changed from 'September 30, 2025' and 'December 31, 2024' (older filing) to 'March 31, 2026' and 'December 31, 2025' (newer filing)
- 'Short-term marketable securities' in older filing changed to 'Marketable securities' in newer filing
- Operating lease terminology remains consistent but figures differ due to different reporting periods
- Three-month comparison period changed from 'Three Months Ended September 30, 2025 vs 2024' (older) to 'Three Months Ended March 31, 2026 vs 2025' (newer)
- Notes:
- The two filings cover different periods (Q1 2026 vs Q3 2025 and nine-month 2025), making some numerical comparisons reflect different operating periods rather than pure operational changes
- Presentation of stockholders' equity statements differs between filings due to different reporting frequencies and periods covered
- Changes in cash flow statement presentation reflect different time periods (nine months ended September 30 vs three months ended March 31)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days.
- Last 90 days1 buy ($166890) · 0 sells — 1 buying insider
- Last 180 days8 buys ($26M) · 0 sells — 4 buying insiders
Cluster buying: 4 different insiders reported open-market purchases (SEC code P) of LRMR within a 30-day window between 2026-02-27 and 2026-02-27. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-06. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LRMR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding LRMR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 6,067,170
- Reported value $27,302,267
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
LRMR had 12,190,367 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
LRMR had 11.7% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.38 days to cover at the same settlement.
- Reported short interest (shares) 12,190,367
- Short interest (% of shares outstanding) 11.7%
- Prior settlement (shares) 11,303,953
- Reported change 7.84%
- Days to cover (reported) 9.38
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Biogen (BIIB)
- Ionis Pharmaceuticals (IONS)
- PTC Therapeutics (PTCT)
- Sage Therapeutics
- Reata Pharmaceuticals
- Voyager Therapeutics (VYGR)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LRMR vs…
LARIMAR THERAPEUTICS INC is found in…
Frequently asked questions
What does LARIMAR THERAPEUTICS INC (LRMR) do?
Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare diseases using its proprietary cell penetrating peptide (CPP) technology platform. The company's lead candidate, nomlabofusp, is designed to deliver frataxin protein to mitochondria in patients with Friedreich's ataxia (FA), a rare, progressive, fatal genetic disease characterized by insufficient frataxin levels.
What sector is LARIMAR THERAPEUTICS INC (LRMR) in?
LARIMAR THERAPEUTICS INC (LRMR) is classified in the Health Care sector. Its industry is Rare disease / orphan drug biotechnology. It trades on NASDAQ.
Who are LARIMAR THERAPEUTICS INC's (LRMR) competitors?
Notable peers of LARIMAR THERAPEUTICS INC (LRMR) include Biogen, Ionis Pharmaceuticals, PTC Therapeutics, Sage Therapeutics and Reata Pharmaceuticals. This peer set is informational only — not financial advice.
Is LARIMAR THERAPEUTICS INC (LRMR) overbought or oversold right now?
LARIMAR THERAPEUTICS INC (LRMR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LRMR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.